February, 2012 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), introduces the
BD™ Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto™ II and
BD FACSCalibur™ flow cytometers. The Kit is for in vitro diagnostic use and provides a single-
tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+
hematopoietic and progenitor cells in a wide range of stem cell sources.
The BD SCE assay simultaneously enumerates the total viable dual-positive CD45+/CD34+
hematopoietic stem cells in absolute counts of CD34+ cells/µL and the percentage of viable
leucocytes (CD45+) that are CD34-positive (CD34+). Transplantation of hematopoietic
progenitor cells is used increasingly in the treatment of blood disorders, malignancies, and
genetic abnormalities. Accurate measure of the CD34 cell count is necessary for dose
requirement protocols in stem cell transplantation.
Regression between CD34+ counts derived using the
BD SCE Kit and a predicate enumeration assay on
the BD FACSCalibur flow cytometer.
The BD SCE Kit is designed for use
with a wide selection of sample types,
including normal and mobilized
peripheral blood, and fresh or frozen
leukophoresis, bone marrow, and cord
blood. The Kit’s pre-mixed antibodies
reduce reagent preparation time to
meet productivity demands of clinical
labs. The BD SCE assay incorporates
BD Trucount™ tubes to determine the
absolute cell count, thereby
eliminating variability associated with
hematology-derived absolute counts.
For more information on the BD Stem
Cell Enumeration Kit, please visit
http://www.bdbiosciences.com/sce.
About BD
BD is a leading global medical technology company that develops, manufactures and sells
medical devices, instrument systems and reagents. The Company is dedicated to improving
people's health throughout the world. BD is focused on improving drug delivery, enhancing the
quality and speed of diagnosing infectious diseases and cancers, and advancing research,
discovery and production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50
countries throughout the world. The Company serves healthcare institutions, life science
researchers, clinical laboratories, the pharmaceutical industry and the general public. For more
information, please visit www.bd.com